Last reviewed · How we verify
XS005 Sorafenib Capsule A - Period 1
XS005 Sorafenib Capsule A - Period 1 is a Small molecule drug developed by Xspray Pharma AB. It is currently in Phase 1 development. Also known as: Regimen B, Regimen C.
At a glance
| Generic name | XS005 Sorafenib Capsule A - Period 1 |
|---|---|
| Also known as | Regimen B, Regimen C |
| Sponsor | Xspray Pharma AB |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XS005 Sorafenib Capsule A - Period 1 CI brief — competitive landscape report
- XS005 Sorafenib Capsule A - Period 1 updates RSS · CI watch RSS
- Xspray Pharma AB portfolio CI
Frequently asked questions about XS005 Sorafenib Capsule A - Period 1
What is XS005 Sorafenib Capsule A - Period 1?
XS005 Sorafenib Capsule A - Period 1 is a Small molecule drug developed by Xspray Pharma AB.
Who makes XS005 Sorafenib Capsule A - Period 1?
XS005 Sorafenib Capsule A - Period 1 is developed by Xspray Pharma AB (see full Xspray Pharma AB pipeline at /company/xspray-pharma-ab).
Is XS005 Sorafenib Capsule A - Period 1 also known as anything else?
XS005 Sorafenib Capsule A - Period 1 is also known as Regimen B, Regimen C.
What development phase is XS005 Sorafenib Capsule A - Period 1 in?
XS005 Sorafenib Capsule A - Period 1 is in Phase 1.
Related
- Manufacturer: Xspray Pharma AB — full pipeline
- Also known as: Regimen B, Regimen C